Patient and Clinician-Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD-Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO-SCALP Study
May 2025
in “
JEADV Clinical Practice
”
Studysummary This study found that using calcipotriene and betamethasone dipropionate cream in a real-world setting significantly improved clinical outcomes and patient quality of life for adults with mild-to-moderate scalp psoriasis, especially among those with higher adherence, demonstrating high treatment satisfaction.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The interim analysis of the PRO-SCALP study evaluated the effectiveness and patient satisfaction of CAL/BDP PAD-cream in treating mild-to-moderate scalp psoriasis in 134 adult patients across Germany, Spain, and the UK. The study found high treatment satisfaction, with significant improvements in quality of life and reduction in symptoms such as itching. Patients with higher adherence (VAS 80−100) experienced better outcomes compared to those with lower adherence (VAS <80). The cream was well-received due to its ease of use and favorable cosmetic properties, enhancing patient compliance. Notably, 77.9% of patients achieved clear or almost clear skin, and 81.5% had a significant reduction in psoriasis severity scores. The treatment also improved psychosocial outcomes, including self-esteem and sleep quality. Despite the lack of a control group, the findings suggest CAL/BDP PAD-cream is a promising treatment for scalp psoriasis, with further long-term studies needed to confirm these results.
